JWCTF Stock JW CAYMAN THERAPEUTICS (JWCTF, $0.53) was the month's biggest loser, descending -20.24%. Expect a Downtrend reversal
at Tickeron.com
Loading...
JW CAYMAN THERAPEUTICS (JWCTF, $0.53) was a top loser this month, diving -2 to $0.53 per share. Of the 782 stocks analyzed in the Biotechnology Industry throughout this month, of them (6) exhibited an Uptrend while of them (3) were in a Downtrend. A.I.dvisor found 57 similar cases when JWCTF's price dropped within one month. In out of those 57 cases, JWCTF's price went up during the month. Based on these historical data, A.I. thinks the odds of a Downtrend reversal for JWCTF are
JWCTF's Indicator enters downward trend
The Aroon Indicator for JWCTF entered a downward trend on November 17, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 104 similar instances where the Aroon Indicator formed such a pattern. In of the 104 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2025. You may want to consider a long position or call options on JWCTF as a result. In of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JWCTF just turned positive on October 28, 2025. Looking at past instances where JWCTF's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.175) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (5.988) is also within normal values, averaging (321.020).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JWCTF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JWCTF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology